MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, PDSB had -$14,977,622 decrease in cash & cash equivalents over the period. -$27,752,012 in free cash flow.

Cash Flow Overview

Change in Cash
-$14,977,622
Free Cash flow
-$27,752,012
Unit: Dollar
Positive Cash Flow Breakdown
    • Net proceeds from issuance of lo...
    • Proceeds from issuance of common...
    • Proceeds from issuance of warran...
    • Others
Negative Cash Flow Breakdown
    • Loan repayment
    • Loan principal payments
    • Interest expense
    • Others

Cash Flow
2025-12-31
Total operating expenses
31,543,959
Interest income
1,217,241
Interest expense
5,338,607
Benefit for income taxes
-1,169,820
Net loss
-34,495,505
Stock-based compensation expense
4,106,606
Issuance of shares in consulting agreements
298,501
Amortization of debt discount
1,553,835
Loss on retirement of debt
-1,107,004
Depreciation expense
21,836
Finance lease amortization expense
38,682
Prepaid expenses and other current assets
173,564
Accounts payable
1,889,580
Accrued expenses
-2,098,987
Operating lease liabilities
0
Net cash used in operating activities
-27,752,012
Purchase of equipment
0
Net cash used in investing activities
0
Proceeds from issuance of pre-funded warrants
1,038,094
Proceeds from issuance of warrants
5,315,811
Proceeds from exercise of pre-funded warrants
100
Proceeds from exercise of stock options
0
Payments of finance lease obligations
61,119
Loan principal payments
6,666,667
Loan repayment
19,000,000
Net proceeds from issuance of loan
18,164,795
Proceeds from issuance of common stock, net of issuance costs
9,709,064
Proceeds from issuance of common stock from at-the-market program, net of issuance costs
4,274,312
Net cash provided by financing activities
12,774,390
Net (decrease) increase in cash and cash equivalents
-14,977,622
Cash and cash equivalents at beginning of period
41,689,591
Cash and cash equivalents at end of period
26,711,969
Unit: Dollar.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Net proceeds fromissuance of loan$18,164,795 Proceeds from issuance ofcommon stock, net of...$9,709,064 Proceeds from issuance ofwarrants$5,315,811 Proceeds from issuance ofcommon stock from...$4,274,312 Proceeds from issuance ofpre-funded warrants$1,038,094 Proceeds from exercise ofpre-funded warrants$100 Net cash provided byfinancing activities$12,774,390 Canceled cashflow$25,727,786 Net (decrease)increase in cash and cash...-$14,977,622 Canceled cashflow$12,774,390 Stock-based compensationexpense$4,106,606 Accounts payable$1,889,580 Amortization of debt discount$1,553,835 Loss on retirement ofdebt-$1,107,004 Issuance of shares inconsulting agreements$298,501 Finance leaseamortization expense$38,682 Depreciation expense$21,836 Loan repayment$19,000,000 Loan principalpayments$6,666,667 Payments of finance leaseobligations$61,119 Net cash used inoperating activities-$27,752,012 Canceled cashflow$9,016,044 Interest income$1,217,241 Benefit for income taxes-$1,169,820 Net loss-$34,495,505 Canceled cashflow$2,387,061 Accrued expenses-$2,098,987 Prepaid expenses andother current assets$173,564 Total operatingexpenses$31,543,959 Interest expense$5,338,607

PDS Biotechnology Corp (PDSB)

PDS Biotechnology Corp (PDSB)